Cargando…

Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

Plasminogen activator inhibitor 1 (PAI-1) has been found to be a bad prognostic factor in a number of tumours but the reason has not been fully explained. The human prostate cancer cell line PC-3 and the human promyelocytic leukaemia cell line HL-60 were used in this study to determine the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwaan, H C, Wang, J, Svoboda, K, Declerck, P J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374508/ https://www.ncbi.nlm.nih.gov/pubmed/10817507 http://dx.doi.org/10.1054/bjoc.2000.1207

Ejemplares similares

Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor
por: Albo, D, et al.
Publicado: (2000)

Divergent Regulation of Alveolar Type 2 Cell and Fibroblast Apoptosis by Plasminogen Activator Inhibitor 1 in Lung Fibrosis
por: Jiang, Chunsun, et al.
Publicado: (2021)

Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue
por: Ferrier, C M, et al.
Publicado: (1999)

Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1
por: Suminami, Y, et al.
Publicado: (2000)

A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?
por: Sillen, Machteld, et al.
Publicado: (2021)

Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours
por: Witte, J H de, et al.
Publicado: (2001)

Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors
por: Jahkola, T, et al.
Publicado: (1999)

Major hepatic resection may suppress the growth of tumours remaining in the residual liver
por: Yokoyama, H, et al.
Publicado: (2000)

Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
por: Levenson, A. S., et al.
Publicado: (1998)

Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity
por: Placencio, Veronica R., et al.
Publicado: (2015)

Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation
por: Gupta, Kamlesh K., et al.
Publicado: (2017)

Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer
por: Witte, J H de, et al.
Publicado: (1999)

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
por: Verheul, H M W, et al.
Publicado: (1999)

Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1
por: Gong, Lihu, et al.
Publicado: (2016)

Inhibition of tumour growth by lipoxygenase inhibitors.
por: Hussey, H. J., et al.
Publicado: (1996)

The Air Liquid-interface, a Skin Microenvironment, Promotes Growth of Melanoma Cells, but not Their Apoptosis and Invasion, through Activation of Mitogen-activated Protein Kinase
por: Hong Yee, Chong, et al.
Publicado: (2010)

Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma
por: Johansson, M, et al.
Publicado: (2000)

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
por: de Witte, J H, et al.
Publicado: (1999)

The topology of plasminogen binding and activation on the surface of human breast cancer cells
por: Andronicos, N M, et al.
Publicado: (2001)

miR-30b, Down-Regulated in Gastric Cancer, Promotes Apoptosis and Suppresses Tumor Growth by Targeting Plasminogen Activator Inhibitor-1
por: Zhu, En-Dong, et al.
Publicado: (2014)

Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth
por: Hess, C, et al.
Publicado: (2001)

Apigenin Attenuates Atherogenesis through Inducing Macrophage Apoptosis via Inhibition of AKT Ser473 Phosphorylation and Downregulation of Plasminogen Activator Inhibitor-2
por: Zeng, Ping, et al.
Publicado: (2015)

Inhibition of tumour growth by marimastat in a human xenograft model of gastric cancer: relationship with levels of circulating CEA
por: Watson, S A, et al.
Publicado: (1999)

Pretreatment apoptosis in carcinoma of the cervix correlates with changes in tumour oxygenation during radiotherapy
por: Sheridan, M T, et al.
Publicado: (2000)

Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer
por: Coulson, J M, et al.
Publicado: (1999)

Stimulation of tumour growth by wound-derived growth factors
por: Abramovitch, R, et al.
Publicado: (1999)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells
por: Jung, Y D, et al.
Publicado: (2001)

Inhibition of angiogenesis and tumour growth by VEGF121–toxin conjugate: differential effect on proliferating endothelial cells
por: Wild, R, et al.
Publicado: (2000)

Lycobetaine acts as a selective topoisomerase IIβ poison and inhibits the growth of human tumour cells
por: Barthelmes, H U, et al.
Publicado: (2001)

Immunohistochemical localisation of tissue plasminogen activator in human brain tumours.
por: Franks, A. J., et al.
Publicado: (1989)

Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
por: Foucré, D., et al.
Publicado: (1991)

Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
por: Heidtmann, H-H, et al.
Publicado: (1999)

Processing of Laminin-5 and Its Functional Consequences: Role of Plasmin and Tissue-type Plasminogen Activator
por: Goldfinger, Lawrence E., et al.
Publicado: (1998)

Activated mesothelial cells produce heparin-binding growth factors: implications for tumour metastases
por: Jayne, D G, et al.
Publicado: (2000)

Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells
por: Pidgeon, G P, et al.
Publicado: (2001)

Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis.
por: Jensen, P. H., et al.
Publicado: (1994)

Blocking Cytochrome c Activity within Intact Neurons Inhibits Apoptosis
por: Neame, Stephen J., et al.
Publicado: (1998)

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions
por: de Wilt, J H W, et al.
Publicado: (2000)

Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumour tissue
por: Lilge, L, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_prvs7eju1hmh6olhv31iu8qjog